Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFLUENCE: Optimizing Fludarabine Exposure During Lymphodepletion for CAR T Cell Therapy in B-ALL
NCT07223021Phase 3Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of fludarabine in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Event Free Survival at 28 days. Started Oct 2025; status: recruiting.
02
Drugs
fludarabine
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07223021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223021.